In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...
In a report released today, Jo Walton from UBS maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Novo Nordisk (NVO – Research Report) yesterday and set a price target of ...
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...
Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely ... The 15 drugs targeted for the next round are expected to be named by early next year, drawing widespread ...
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
The Nordisk Film & TV Fond has teamed with the Göteborg Film Festival to launch the Nordic Series Awards, a new award to honor Nordic drama series. The Nordic Series Award replaces the Nordisk ...
Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
On Sept. 16 Novo Nordisk (NYSE: NVO) and Korro Bio (NASDAQ: KRRO) announced that they'd be starting a new drug-development collaboration worth hundreds of millions of dollars, in an area that most ...
in a pre-IPO round, said people aware of the development. Investors including Quadria Capital and Denmark-based pharmaceutical major Novo Nordisk are among those interested in a minority stake and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback